These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 11768629)
1. High-dose therapy with ropinirole in patients with Parkinson's disease. Müngersdorf M; Sommer U; Sommer M; Reichmann H J Neural Transm (Vienna); 2001; 108(11):1309-17. PubMed ID: 11768629 [TBL] [Abstract][Full Text] [Related]
2. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias. Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640 [TBL] [Abstract][Full Text] [Related]
4. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. Im JH; Ha JH; Cho IS; Lee MC J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999 [TBL] [Abstract][Full Text] [Related]
5. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Giménez-Roldán S; Esteban EM; Mateo D Clin Neuropharmacol; 2001; 24(6):346-51. PubMed ID: 11801810 [TBL] [Abstract][Full Text] [Related]
6. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I; Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525 [TBL] [Abstract][Full Text] [Related]
7. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Cristina S; Zangaglia R; Mancini F; Martignoni E; Nappi G; Pacchetti C Clin Neuropharmacol; 2003; 26(3):146-50. PubMed ID: 12782917 [TBL] [Abstract][Full Text] [Related]
8. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304 [TBL] [Abstract][Full Text] [Related]
10. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F; J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968 [TBL] [Abstract][Full Text] [Related]
11. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029 [TBL] [Abstract][Full Text] [Related]
12. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339 [TBL] [Abstract][Full Text] [Related]
13. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Parkinson Study Group CALM Cohort Investigators Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655 [TBL] [Abstract][Full Text] [Related]
14. Ropinirole: new preparation. Wait for more convincing data. Prescrire Int; 1998 Apr; 7(34):36-8. PubMed ID: 10183378 [TBL] [Abstract][Full Text] [Related]
15. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias. Bachmann CG; Zapf A; Brunner E; Trenkwalder C Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662 [TBL] [Abstract][Full Text] [Related]
16. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848 [TBL] [Abstract][Full Text] [Related]
17. A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease. Zesiewicz TA; Chriscoe S; Jimenez T; Upward J; Davy M; VanMeter S Neurodegener Dis Manag; 2017 Feb; 7(1):61-72. PubMed ID: 28120630 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
19. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Rascol O; Lees AJ; Senard JM; Pirtosek Z; Montastruc JL; Fuell D Clin Neuropharmacol; 1996 Jun; 19(3):234-45. PubMed ID: 8726542 [TBL] [Abstract][Full Text] [Related]
20. Effect of ropinirole on visuo-motor test in newly diagnosed Parkinson's disease patients. Badarny S; Stern A; Susel Z; Honigman S; Hocherman S Acta Neurol Scand; 2006 May; 113(5):294-300. PubMed ID: 16629764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]